Stockman Wealth Management Inc. Increases Stake in Becton Dickinson and Co (BDX)

Stockman Wealth Management Inc. grew its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 19.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,630 shares of the medical instruments supplier’s stock after buying an additional 270 shares during the period. Stockman Wealth Management Inc.’s holdings in Becton Dickinson and were worth $425,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Ascension Asset Management LLC boosted its position in Becton Dickinson and by 4.2% during the 2nd quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock worth $1,191,000 after purchasing an additional 200 shares during the period. Bfsg LLC boosted its position in Becton Dickinson and by 1.9% during the 2nd quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock worth $2,519,000 after purchasing an additional 201 shares during the period. Toth Financial Advisory Corp boosted its position in Becton Dickinson and by 0.8% during the 2nd quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock worth $5,986,000 after purchasing an additional 203 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in Becton Dickinson and by 0.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock worth $12,181,000 after purchasing an additional 204 shares during the period. Finally, Spearhead Capital Advisors LLC boosted its position in Becton Dickinson and by 1.4% during the 3rd quarter. Spearhead Capital Advisors LLC now owns 15,525 shares of the medical instruments supplier’s stock worth $3,887,000 after purchasing an additional 218 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on the stock. Wells Fargo & Co upped their price objective on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Piper Jaffray Companies decreased their price objective on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research report on Tuesday. Royal Bank of Canada reissued a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Barclays assumed coverage on shares of Becton Dickinson and in a research report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price objective for the company. Finally, Citigroup upped their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $254.71.

NYSE:BDX opened at $237.94 on Wednesday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The stock has a market capitalization of $63.03 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 1.40 and a beta of 1.19. Becton Dickinson and Co has a 1-year low of $209.91 and a 1-year high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.93. The business had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The company’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.40 EPS. As a group, sell-side analysts expect that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/07/stockman-wealth-management-inc-increases-stake-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Further Reading: What are the benefits of buying treasury bonds?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply